Pair Name	Alpha-Hederin, Cisplatin
Disease Info	[ICD-11: 2B72.Z]	Gastric cancer		Investigative
Biological Phenomena	Induction-->ROS accumulation
Gene Regulation	Up-regulation	Expression	ROS1	hsa6098
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	APAF1	hsa317
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Up-regulation	Expression	CYCS	hsa54205
In Vitro Model	SGC-7901	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0520
	HGC-27	Gastric carcinoma	Homo sapiens (Human)	CVCL_1279
	MGC-803	Gastric mucinous adenocarcinoma	Homo sapiens (Human)	CVCL_5334
In Vivo Model	The collected HGC-27 cells were washed in serum-free DMEM, suspended in 100 μl of PBS and subcutaneously implanted into the dorsal region of nude mice.
Result	α-Hederin enhances cisplatin-induced anti-tumour effects in GC both in vitro and in vivo by promoting the accumulation of ROS and decreasing MMP. Our data strongly suggested that α-Hederin is a promising candidate for intervention in gastric cancer.